These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 11449262)
1. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Perutz MF; Windle AH Nature; 2001 Jul; 412(6843):143-4. PubMed ID: 11449262 [TBL] [Abstract][Full Text] [Related]
2. [Aggregation and toxicity of the proteins with polyQ repeats]. Leźnicki P Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359 [TBL] [Abstract][Full Text] [Related]
3. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Hirabayashi M; Inoue K; Tanaka K; Nakadate K; Ohsawa Y; Kamei Y; Popiel AH; Sinohara A; Iwamatsu A; Kimura Y; Uchiyama Y; Hori S; Kakizuka A Cell Death Differ; 2001 Oct; 8(10):977-84. PubMed ID: 11598795 [TBL] [Abstract][Full Text] [Related]
4. Caspase activity sows the seeds of neuronal death. Yuan J; Yankner BA Nat Cell Biol; 1999 Jun; 1(2):E44-5. PubMed ID: 10559896 [No Abstract] [Full Text] [Related]
6. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109 [TBL] [Abstract][Full Text] [Related]
7. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780 [TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Ross CA; Margolis RL; Becher MW; Wood JD; Engelender S; Cooper JK; Sharp AH Prog Brain Res; 1998; 117():397-419. PubMed ID: 9932422 [TBL] [Abstract][Full Text] [Related]
9. Scale-free neurodegeneration: cellular heterogeneity and the stretched exponential kinetics of cell death. Clarke G; Lumsden CJ J Theor Biol; 2005 Apr; 233(4):515-25. PubMed ID: 15748912 [TBL] [Abstract][Full Text] [Related]
10. Polyglutamine disease and neuronal cell death. Paulson HL; Bonini NM; Roth KA Proc Natl Acad Sci U S A; 2000 Nov; 97(24):12957-8. PubMed ID: 11058149 [No Abstract] [Full Text] [Related]
11. Therapeutic strategies to retard neuronal cell death in neurodegenerative diseases. Davis RE Curr Opin Investig Drugs; 2001 May; 2(5):654-6. PubMed ID: 11569942 [No Abstract] [Full Text] [Related]
12. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Woulfe JM Neuropathol Appl Neurobiol; 2007 Feb; 33(1):2-42. PubMed ID: 17239006 [TBL] [Abstract][Full Text] [Related]
18. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Stavrovskaya IG; Kristal BS Free Radic Biol Med; 2005 Mar; 38(6):687-97. PubMed ID: 15721979 [TBL] [Abstract][Full Text] [Related]